GMN
0.002
100%
EV1
0.011
-31.3%
EVR
0.005
25%
TOU
0.03
-25%
OVT
0.005
25%
BCB
0.004
-20%
CMP
0.31
21.6%
TMS
0.012
-20%
AYT
0.006
20%
EPM
0.005
-16.7%
LDR
0.135
17.4%
WSR
0.005
-16.7%
BDG
0.055
17%
AZL
0.006
-14.3%
NAG
0.018
12.5%
IXR
0.006
-14.3%
RR1
0.009
12.5%
KGD
0.006
-14.3%
HE8
0.01
11.1%
GLA
0.007
-12.5%
ADR
0.011
10%
PDN
6.2
-9.2%
PLY
0.22
10%
MDR
0.1
-9.1%
CRS
0.061
8.9%
PER
0.01
-9.1%
ADX
0.025
8.7%
SMX
0.05
-9.1%
GTE
0.025
8.7%
AII
2.2
-8.7%
VSR
0.013
8.3%
SVL
0.096
-8.6%
ERM
0.14
7.7%
APC
0.011
-8.3%
CZR
0.3
7.1%
THB
0.012
-7.7%
OZM
0.061
7%
VR1
0.024
-7.7%
FGR
0.046
7%
VHM
0.26
-7.1%

Short Video: Tryptamine Therapeutics (ASX:TYP): Clinical-stage biotech focused on psychedelic drug development

Tryptamine Therapeutics Limited (ASX:TYP) is a clinical-stage biotech and its current primary focus is the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs. Tryptamine Therapeutics CEO and Executive Director Jason Carroll speaks with The Stock Network’s Lel Smits.

🧬 Phase 2a clinical trial now underway – investigating the treatment of Irritable Bowel Syndrome, or IBS
🏥 Recently dosed the first patient at Massachusetts General Hospital, U.S.A
🍄 First time this prestigious hospital has administered psilocybin in a clinical setting
‍
Watch the full interview ⚡ https://youtu.be/iug95UNKcMs

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved